Australian medicines exports have declined by 30% in one year, and Medicines Australia says this highlights the enormous challenges facing the local industry as they struggle to remain competitive in the global pharmaceutical industry.
Five years ago, medicines were Australia’s largest manufactured export, bringing in more than $4 billion to the local economy, Medicines Australia says.
Today, manufactured medicines have slipped to second place behind the motor vehicle industry. If the trend continues, medicine manufacturing will shortly drop to third.
The latest figures released by the Australian Bureau of Statistics reveal that in the first six months of 2015, Australian manufacturing exports were $1.06 Billion, compared to $1.49 Billion in the first half of 2014, representing a 28.5% decline. Pharmaceutical exports were 30% lower in June 2015, compared to June 2014.
Such a dramatic fall in the rankings should be ringing alarm bells in Canberra, Medicines Australia says.
At a time of growing demand for innovative, safe and effective medicine products in Asia, particularly in China, Australia is set to miss out on an enormous economic and job creating opportunity if our politicians fail to get the policy settings right, it says.
It urges the Government to do more if it wants to fulfil its promise to encourage growth in the biopharmaceutical sector.
“A shrinking Australian dollar can help to make our exports more competitive, but on its own, it will not reverse the trend,” Medicines Australia says.
“A lower dollar also cannot compensate for the enormous challenges facing industry and the broader Australian economy as the mining boom comes to an end.”
In a submission to the current Senate inquiry into Australia’s Innovation System, Medicines Australia outlined key principles to invigorate the Australian medicines industry, which included:
- Secure the existing investment we have in Australia to ensure it stays here;
- Encourage the development of Australia’s local bio-pharmaceutical sector; and
- Attract new direct foreign investment to Australia.
The submission argued that by following these key principles, Australia could take advantage of the Asia boom and at least double current medicine exports, but with stiff competition from nations such as Singapore and Japan, the time to act is running out.
Medicines Australia says it is encouraged to see that the Australian Parliament is beginning to identify science and innovation as a key future economic and employment driver for this country, however, the rhetoric needs to be matched with action.
“To further support the Australian pharmaceutical industry, Government must urgently identify additional ways to encourage more local innovation and adopt policies that will lead to more research and development, clinical trials, and advanced manufacturing investment,” it says.
“This is the opportunity that Medicines Australia has been highlighting to policy makers for some time.”